News and Announcements
Author-IT Finalizes $13.5m NZ Series C Funding & Releases DocuveraTM
- Published August 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Author-it is a fast growing SaaS business that provides cloud based, authoring and content management solutions, purpose-built for the life sciences industry where documentation accounts for ~25% of the average cost of bringing a drug to market.
This past year was both successful and eventful for Author-it Software Corporation, a world leader in component authoring and content management solutions for the Life Sciences industry. The company finalized a $13.5m NZ Series C funding that had commenced earlier in 2016. In addition, Author-it formally released DocuveraTM in June 2017. Docuvera is a new transformative software platform used to create Life Science documentation for global companies. Docuvera dramatically increases compliance and lowers operating costs by 50%. Lastly, Author-it continued to sign new customers from the top tiers of global Life Sciences companies and add to its considerable and prestigious customer base.
ABOUT AUTHOR-IT
Author-it Software Corporation (ASC) is a world leader in component authoring solutions. We enable the efficient authoring, sharing and reuse of information across a number of content types. Reuse of information drives massive process and content production improvements including increased productivity, reduced time to market, better accuracy and consistency, improved customer experience and substantial cost savings. Author-it solutions have been built in partnership with our clients and are the culmination of more than 20 years component authoring experience.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
